Carcinoma of the vulva

Author(s): Rutledge F, Smith JP, Franklin EW

Abstract

Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma (VSCC) is an aggressive clinical entity. Current diagnostic guidelines for premalignant lesions are ambiguous, and their molecular profile and progression events are still unclear. We selected 75 samples, from 40 patients, including 33 VSCC, 8 verrucous carcinomas (VC), 13 differentiated-type vulvar intraepithelial neoplasia (dVIN), 11 suspicious for dVIN (?dVIN), 6 differentiated exophytic vulvar intraepithelial lesions (DE-VIL), 2 vulvar acanthosis with altered differentiation (VAAD), and 2 usual-type vulvar intraepithelial neoplasia (uVIN/HSIL). Invasive and precursor lesions were matched in 29 cases. Clinical information, p16 immunohistochemistry, and mutation analysis were performed on all lesions. All dVIN, ?dVIN, DE-VIL, and VAAD were p16 negative, all uVIN/HSIL were p16 positive. In the HPV-independent group, mutations were identified in 6 genes: TP53 (n = 40), PIK3CA (n = 20), HRAS (n = 12), MET (n = 5), PTEN (n = 4), and BRAF (n = 1). TP53 mutations occurred in 73% (22/30) VSCC, 85% (11/13) dVIN, 70% (7/10) ?dVIN and no VC (0/8), DE-VIL (0/6) nor VAAD (0/2). Basal atypia was the only reliable feature of TP53 mutations. ?dVIN lesions that were non-acanthotic and atypical but obscured by inflammation, all harbored TP53 mutations. In lesions without TP53 mutations, PIK3CA (50% VC, 33% DE-VIL, 100% VAAD, 40% VSCC) and HRAS (63% VC, 33% DE-VIL, 0% VAAD, 20% VSCC) mutations were found. Mutational progression from in situ to invasive was seen (7/26, 27%) and usually involved TP53 (4/26, 15%). Cases with TP53 and PIK3CA co-mutations had the worse clinical outcomes (p < 0.001). We recommend testing for p53 in all HPV-independent lesions suspicious for dVIN, even in the presence of marked inflammation or non-acanthotic skin, particularly when close to a margin. VC, VAAD, and DE-VIL, were almost never mutated for TP53, but instead often harbored PIK3CA and HRAS mutations. In VSCC, combined TP53 and PIK3CA mutations may inform prognosis.

Similar Articles

Trends in the incidence of invasive and in situ vulvar carcinoma

Author(s): Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA

New aspects of vulvar cancer: changes in localization and age of onset

Author(s): Hampl M, Deckers-Figiel S, Hampl JA, Rein D, Bender HG

The impact of improving outcomes guidance on surgical management of vulval squamous cell cancer in southwest England (1997-2002)

Author(s): Falconer AD, Hirschowitz L, Weeks J, Murdoch J; South West Gynaecology Tumour Panel

Groin dissection practices among gynecologic oncologists treating early vulvar cancer

Author(s): Levenback C, Morris M, Burke TW, Gershenson DM, Wolf JK, et al.

A proposed glossary of terminology related to the surgical treatment of vulvar carcinoma

Author(s): Micheletti L, Preti M, Zola P, Zanotto Valentino MC, Bocci C, et al.

FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers

Author(s): Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S

Squamous carcinoma of the vulva: results of treatment, 1938 to 1976

Author(s): Benedet JL, Turko M, Fairey RN, Boyes DA

Changing trends in the surgical treatment of invasive carcinoma of the vulva

Author(s): Cavanagh D, Roberts WS, Bryson SC, Marsden DE, Ingram JM, et al.

Management of regional lymph nodes and their prognostic influence in vulvar cancer

Author(s): Hacker NF, Berek JS, Lagasse LD, Leuchter RS, Moore JG

Squamous vulvar cancer: a clinically based individualization of treatment

Author(s): Rodolakis A, Diakomanolis E, Voulgaris Z, Akrivos T, Vlachos G, et al.

Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva

Author(s): Raspagliesi F, Hanozet F, Ditto A, Solima E, Zanaboni F, et al.

Carcinoma of the vulva

Author(s): Beller U, Quinn MA, Benedet JL, Creasman WT, Ngan HY

Changes in the management of vulval cancer

Author(s): Dhar KK, Woolas RP

Individualization of treatment for stage I squamous cell vulvar carcinoma

Author(s): Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Leuchter RS